Tag: NBTXR3
NANOBIOTIX ESTABLISHES RECOMMENDED DOSE FOR REGISTRATION STUDY EVALUATING NBTXR3 + ANTI-PD-1 COMBINATION IN PATIENTS WITH METASTATIC HEAD AND NECK CANCER AND IMMUNOTHERAPY RESISTANT – 09/21/2022 at 22 :20
• Recommended dose for phase 2 of the dose escalation part of study 1100, established at 33% of the tumor volume (GTV) in the three cohorts of the study. •…
NANOBIOTIX AND LIANBIO ANNOUNCE THE RECRUITMENT OF THE FIRST PATIENT IN ASIA FOR THE NANORAY-312 PHASE 3 TRIAL, EVALUATING NBTXR3 IN THE MANAGEMENT OF HEAD AND NECK CANCERS – 09/07/2022 at 22:20
• The implementation of the pivotal Phase 3 trial of Nanobiotix in the treatment of head and neck cancers is progressing as planned: LianBio, partner of Nanobiotix, recruited the first…
Nanobiotix announces encouraging results for its lead product NBTXR3
Nanobiotix presented new data to the American Society for Clinical Oncolgy. The two phase 1b/2 clinical trials for its lead product NBTXR3 had shown favorable results in cancers of the…
Nanobiotix: new encouraging data for NBTXR3 – 06/06/2022 at 08:12
(AOF) – Nanobiotix presents at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting new data highlighting the potential of NBTXR3, a first-in-class radioenhancer, in combination with concurrent chemotherapy…
New data associating NBTXR3 with preoperative chemotherapy indicate that NBTXR3 may fit into the treatment of head and neck cancer and other solid tumors – 06/05/2022 at 15:00
Data presented at the 2022 American Society for Clinical Oncology Annual Meeting• NBTXR3 is being developed in order to be able to be integrated into therapeutic management in oncology: the…
Nanobiotix announces the publication of the study of a first clinical case of treatment with NBTXR3 in pancreatic cancer – 02/09/2022 at 22:15
• A peer-reviewed clinical case reports preliminary data on the first-in-human administration of NBTXR3 in the treatment of pancreatic cancer not eligible for surgery, demonstrating the feasibility of injection and…
Nanobiotix announces the publication of new preclinical data describing the potential of combining NBTXR3 with anti-PD-1 and anti-CTLA-4 immunotherapies – 01/26/2022 at 22:29
Data published in the International Journal of Nanobiotechnology – New preclinical data (published in a peer-reviewed journal) from a model of anti-PD-1 resistant lung cancer shows that adding NBTXR3 to…